IRMD · Iradimed Corp
$85.40
+0.10 (+0.12%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$1.10B
Shares
12.79M
Volume · Oct 2
119.45K
Avg daily vol (3M)
127.7K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$85.40
Open$86.14
Day$84.53–86.27
52W close$71.08–105.15
Avg vol 30d125K
Short int700K · 5.5% float · 5.7d
Short vol53%
Last earningsJul 31, 2026
DataJan 2020–Oct 2026
Filing10-Q · Jul 31
Up next
Next earnings call
Nov 1, 2026
Est · unconfirmed
· in 4 wks
filed Jul 31, 2026
call held Jul 31, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$86.34M
Trailing 12 months
Net income (TTM)
$23.05M
Trailing 12 months
Revenue growth YoY
+0.3%
Year over year
Operating margin
31.9%
Trailing 12 months
P / E (TTM)
47.7
Trailing earnings · reciprocal yield 2.1%
FCF yield
2.3%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$59.08M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.3%
Year over year · more shares
Price change (1Y)
+20.1%
Trailing year
Short interest
5.5%
Latest settlement · 5.7 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Excellent
Quant / Vol
Moderate
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−9%
below
Price vs 50-day avg
−2%
below
RSI (14)
49
neutral
MACD trend
Positive
52-week position
42%
mid-range
Momentum
relative strength
1-month return
−1%
trailing
6-month return
−9%
trailing
YTD return
−12%
this year
Relative strength
−21%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $87 › 200d $94 — 200d above 50d
Institutional flow
Flat
1 of 215 funds reported for Sep 30 · net 0 sh shares
Insider flow
Distributing
Net -$122.6K over 90 days · 100% sells
Short interest
Rising
5.47% of float · ▲ +0.4% MoM · 5.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
215 holders — mid 3-yr range
Squeeze score
56
elevated · 0–100
Fundamentals
Revenue growth
+14%
Y/Y
Gross margin
77%
contracting
EPS growth
+17%
Y/Y
Free cash flow
$17.2M
Valuation
P/E 47.9
rich
Quant / Vol
risk profile
Volatility
31%
annualized · 1-yr
Max drawdown
−22%
past year
ATR
2.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Jun 30, 2026
third quarter of 2026
Revenue
Initiated
$23M – $24.5M
prior qtr $20.47M
midpoint +16.0% QoQ
Non-GAAP diluted earnings per share
Initiated
$0.54 – $0.59
GAAP diluted earnings per share
Initiated
$0.49 – $0.54
prior qtr $0.41
midpoint +25.6% QoQ
full year 2026
Revenue
Initiated
$91M – $96M
prior FY $83.81M
midpoint +11.6% Y/Y
GAAP diluted earnings per share
Initiated
$1.90 – $2.05
prior FY $1.75
midpoint +12.9% Y/Y
Non-GAAP diluted earnings per share
Initiated
$2.09 – $2.24
Guided vs delivered
· last 8 settled
Revenue
fourth quarter of 2023
guided $16.9M – $17.4M
$17.45M
Beat +1.8%
Revenue
full-year 2023
guided $65M – $65.5M
$65.56M
Beat +0.5%
GAAP diluted earnings per share
full-year 2023
guided $1.34 – $1.37
$1.35
In line
Revenue
third quarter of 2023
guided $16.1M – $16.3M
$16.5M
Beat +1.9%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−9%
Bearish
Price vs 50-day avg
−2%
Neutral
RSI (14)
49
Neutral
MACD trend
Positive
Bullish
52-week position
42%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $87 › 200d $94 — 200d above 50d
Institutional flow
Flat
1 of 215 funds reported for Sep 30 · net 0 sh shares
Insider flow
Distributing
Net -$122.6K over 90 days · 100% sells
Short interest
Rising
5.47% of float · ▲ +0.4% MoM · 5.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
215 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $71
Now $85 · 42%
Range high $105
vs 200-day avg -9%
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IRMD
this stock
Iradimed Corp
|
$1.10B | -12.2% | +14.4% | 47.9 | 5.5% |
|
ABT
Abbott Laboratories
|
$174.90B | -22.2% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -10.1% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -21.6% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -55.3% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IRMD | -0.4% | -1.4% | -8.7% | -1.0% | -12.2% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -0.2% | -0.9% | -20.9% | -1.9% | -25.1% |